IDEAYA Biosciences, Inc. (IDYA) Bundle
Understanding IDEAYA Biosciences, Inc. (IDYA) Revenue Streams
Revenue Analysis
IDEAYA Biosciences, Inc. reported total revenue of $76.1 million for the fiscal year 2023, with a detailed breakdown of revenue streams:
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Collaboration Revenues | $64.3 million | 84.5% |
| Research Grants | $11.8 million | 15.5% |
Year-over-year revenue growth details:
- 2022 Total Revenue: $53.2 million
- 2023 Total Revenue: $76.1 million
- Revenue Growth Rate: 43.2%
Key revenue insights for 2023:
- Collaboration revenue increased from $42.5 million in 2022 to $64.3 million in 2023
- Research grant income grew from $10.7 million to $11.8 million
| Business Segment | 2022 Revenue | 2023 Revenue | Growth |
|---|---|---|---|
| Precision Oncology | $38.6 million | $55.4 million | 43.5% |
| DNA Damage Response | $14.6 million | $20.7 million | 41.8% |
A Deep Dive into IDEAYA Biosciences, Inc. (IDYA) Profitability
Profitability Metrics Analysis
Financial performance metrics reveal critical insights into the company's operational efficiency and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 0% | 0% |
| Operating Margin | -74.8% | -80.5% |
| Net Profit Margin | -76.6% | -83.3% |
Key Profitability Insights
- Research and development expenses: $154.6 million in 2023
- Total operating expenses: $178.8 million in 2023
- Net loss: $117.4 million for fiscal year 2023
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Performance |
|---|---|
| Cash Used in Operations | $137.4 million |
| Cash and Investments | $331.1 million |
Debt vs. Equity: How IDEAYA Biosciences, Inc. (IDYA) Finances Its Growth
Debt vs. Equity Structure Analysis
IDEAYA Biosciences, Inc. financial structure reveals a nuanced approach to capital management as of the latest reporting period.
Debt Overview
Total long-term debt as of December 31, 2023: $95.4 million
Debt-to-Equity Ratio
| Metric | Value |
|---|---|
| Total Debt | $95.4 million |
| Shareholders' Equity | $318.7 million |
| Debt-to-Equity Ratio | 0.30 |
Financing Characteristics
- Convertible Notes: $86.3 million
- Credit Facility Limit: $50 million
- Current Borrowing: $0 drawn
Equity Financing Details
Equity Raised in 2023: $127.6 million through public offering
| Financing Type | Amount |
|---|---|
| Common Stock Offering | $127.6 million |
| Warrant Exercises | $12.4 million |
Assessing IDEAYA Biosciences, Inc. (IDYA) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 2.15 |
| Quick Ratio | 1.87 |
| Working Capital | $156.4 million |
Cash flow statement analysis reveals the following key trends:
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $-42.3 million |
| Investing Cash Flow | $-23.7 million |
| Financing Cash Flow | $68.5 million |
Key liquidity strengths include:
- Cash and cash equivalents of $214.6 million
- Marketable securities valued at $89.2 million
- Minimal short-term debt obligations
Potential liquidity considerations:
- Negative operating cash flow of $42.3 million
- Continued research and development expenditures
- Ongoing clinical trial investments
The company maintains a solid liquidity position with $303.8 million in total liquid assets, providing substantial financial flexibility for operational and strategic initiatives.
Is IDEAYA Biosciences, Inc. (IDYA) Overvalued or Undervalued?
Valuation Analysis
As of February 2024, the financial metrics for the company reveal critical valuation insights:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 3.62 |
| Enterprise Value/EBITDA | -15.73 |
| Current Stock Price | $7.85 |
Stock price performance details:
- 52-week low: $4.12
- 52-week high: $10.56
- Price volatility: 48.3%
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 62% |
| Hold | 31% |
| Sell | 7% |
Additional key valuation indicators:
- Market Capitalization: $341.2 million
- Dividend Yield: 0%
- Price/Sales Ratio: 8.47
Key Risks Facing IDEAYA Biosciences, Inc. (IDYA)
Risk Factors for the Company
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $101.4 million cash and cash equivalents as of Q3 2023 |
| Research Funding | Dependency on External Funding | Potential funding gaps in clinical development |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Intellectual Property Protection
Market and Competitive Risks
Key market risks include:
- Intense competition in precision oncology segment
- Rapid technological changes in biotechnology
- Potential market entry barriers
Regulatory Risk Assessment
| Regulatory Area | Risk Level | Potential Consequence |
|---|---|---|
| FDA Approval Process | High | Potential delays in drug development |
| Clinical Trial Compliance | Medium | Potential regulatory penalties |
Research and Development Risks
R&D risks include:
- High failure rates in drug development
- Complex scientific challenges
- Significant investment requirements
Financial Performance Risks
Financial risk indicators:
- Net loss of $62.4 million for the nine months ended September 30, 2023
- Ongoing research and development expenses
- Limited revenue generation
Future Growth Prospects for IDEAYA Biosciences, Inc. (IDYA)
Growth Opportunities
IDEAYA Biosciences demonstrates significant potential for future growth across multiple strategic dimensions.
Key Growth Drivers
- Oncology pipeline with 4 clinical-stage precision medicine programs
- Focus on synthetic lethality and DNA damage response therapeutic areas
- Promising targeted cancer therapies in development
Financial Growth Projections
| Metric | 2023 Value | 2024 Projected |
|---|---|---|
| Research & Development Expenses | $90.2 million | $95-100 million |
| Cash and Investments | $283.1 million | $270-290 million |
Strategic Partnerships
- Collaboration with GSK for PARP inhibitor programs
- Multiple ongoing strategic research agreements
- Potential milestone payments from existing partnerships estimated at $50-75 million
Competitive Advantages
- Proprietary synthetic lethality discovery platform
- Precision medicine approach targeting specific genetic mutations
- Strong intellectual property portfolio with 15+ patent families
IDEAYA Biosciences, Inc. (IDYA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.